Objective:To assess the efficacy and safety of
omalizumab in patients with
allergic rhinitis(AR) in a meta-analysis of clinical trial results, and provide evidence for the clinical treatment of AR.Method:Pubmed, Medline, Cochrane and Embase were searched through August 2014 using the terms '
allergic rhinitis,
omalizumab, efficacy, safety, and randomized controlled trial(RCT)'without language restriction. Relevant reviews, publications, and abstracts of meetings were also retrieved. RevMan5.3 software was used for meta-analysis after data extraction. Result: Nine RCTs were included(n =1764).Of the 1764 participants,859 patients were treated by
omalizumab and the other 905 received a placebo.The meta-analysis revealed that patients treated with
omalizumab had significantly reduced total and individual symptoms scorescompared with the placebo group(P <0.05). And there was no significantly differences in adverse events between placebo and
omalizumab(P <0.05).The WMD rate and 95%CI were as follows:total nasal symptom scores(0.04, - 0.10 to 0.19), rhinorrhea(-0.32, -0.44 to -0.21), nasal stuffiness(-0.33,-0.38 to -0.27), nasal
itching (-0.08,-0.25 to 0.09), and sneezing(-0.24, -0.27 to -0.21), and non-nasal symptoms scores(0.30,0.04 to 0.55).Conclusion:Compared to the placebo,
omalizumab can effectively and safely reduce symptoms scores of patients with AR.